NasdaqCM - Nasdaq Real Time Price USD

Daré Bioscience, Inc. (DARE)

2.8900

-0.0100

(-0.34%)

At close: May 7 at 4:00:01 PM EDT

2.9100

+0.02

+(0.69%)

After hours: May 7 at 5:43:41 PM EDT

Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025

SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, May 13, 2025, to review its financial results for the quarter ended March 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free). The confe

GlobeNewswire yesterday

DARE
-0.34%
Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women’s Health Innovation

Presentation will focus on corporate communications strategies for unveiling an innovative expanded business strategyDaré recently announced its new dual-path approach for its proprietary Sildenafil Cream formulation and is targeting availability via prescription in Q4 2025 SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced that Sabrina M

GlobeNewswire 14 days ago

DARE
-0.34%
Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year

Daré unveiled its new dual-path approach for its proprietary Sildenafil Cream formulation after urging on the part of the healthcare community and hearing the demand from womenDaré is targeting availability of its proprietary Sildenafil Cream formulation via prescription in Q4 2025 SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced that

GlobeNewswire 30 days ago

DARE
-0.34%
Q4 2024 Dare Bioscience Inc Earnings Call

Q4 2024 Dare Bioscience Inc Earnings Call

Thomson Reuters StreetEvents last month

DARE
-0.34%
Dare Bioscience Inc (DARE) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial ...

Dare Bioscience Inc (DARE) reports decreased expenses and secures significant funding, but faces ongoing financial hurdles and strategic uncertainties.

GuruFocus.com last month

DARE
-0.34%
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

Dare Bioscience (DARE) delivered earnings and revenue surprises of 3.03% and 101.60%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

DARE
-0.34%
Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

With increasing demand for needed treatments designed for women, Daré is taking action to make its proprietary Sildenafil Cream formulation available via prescription this yearEnables women to access a solution that they want and needCreates an opportunity to accelerate revenue generation from this proprietary formulation Daré expects to start recording revenue and cash flow in the 4th quarter of this year Conference call today at 4:30 p.m. ET to discuss the expanded business strategy to integra

GlobeNewswire last month

DARE
-0.34%
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and well-being of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Monday, March 31, 2025, to review its financial results for the year ended December 31, 2024, and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free). The conference ID number for the call is 9767621. Th

GlobeNewswire last month

DARE
-0.34%
Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant

Ongoing Phase 1 study is funded by a foundation grant Daré received a royalty-free, exclusive license to the US patents SAN DIEGO and LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, and Theramex, a leading, global specialty pharmaceutical company dedicated to women and their health, announced today that they entered into a co-development and licensing agreement for a potential first-in-category biodegr

GlobeNewswire 2 months ago

DARE
-0.34%
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management Essentially all cervical cancer cases worldwide are caused by HPV infection Up to $2 million in grant funding may be provided by NIAID to support DARE-HPV development, bringing total non-dilutive funding for DARE-HPV advancement to up to $12 million SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NAS

GlobeNewswire 2 months ago

DARE
-0.34%
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health series at this year’s conference to highlight the importance of innovation and growing visibility around women’s health. SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, announced today that Sabrina Martucci Johnson, President and CEO of Daré Bioscience, will be speaking o

GlobeNewswire 3 months ago

DARE
-0.34%
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)

FSAD is clinically analogous to erectile dysfunction in men.To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first FDA approval for FSAD. Market research estimates approximately 10 million women in the U.S. are distressed from experiencing symptoms associated with FSAD and are actively seeking solutions to improve their condition. SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a l

GlobeNewswire 4 months ago

DARE
-0.34%
Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

Published data show that age and use of hormonal contraception did not impact the efficacy of Sildenafil CreamSAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that additional data from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for female sexual arousal

GlobeNewswire 4 months ago

DARE
-0.34%
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and Other Conditions Requiring Precise, Prolonged Treatment SAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, to

GlobeNewswire 4 months ago

DARE
-0.34%
Q3 2024 Dare Bioscience Inc Earnings Call

Q3 2024 Dare Bioscience Inc Earnings Call

Thomson Reuters StreetEvents 5 months ago

DARE
-0.34%
Dare Bioscience Inc (DARE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...

Dare Bioscience Inc (DARE) secures significant funding and progresses with FDA interactions, despite facing increased operational costs and financial hurdles.

GuruFocus.com 5 months ago

DARE
-0.34%
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates

Dare Bioscience (DARE) delivered earnings and revenue surprises of 8.33% and 98.64%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

DARE
-0.34%
Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate – pivotal Phase 3 contraceptive efficacy study recruiting across the United States; foundation grant announced yesterday will provide funding to allow Daré to expand the number of clinical sites to accelerate the development timeline Sildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female s

GlobeNewswire 5 months ago

DARE
-0.34%
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites

- Grant funds will support activities that will aid in the identification and development of a novel non-hormonal intravaginal contraceptive product candidate. - Grant will also provide funding to allow Daré to expand the number of clinical sites in the ongoing Ovaprene® pivotal study to accelerate the development timeline. SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced it entered in

GlobeNewswire 5 months ago

DARE
-0.34%
Dare Bioscience (DARE) Upgraded to Buy: Here's What You Should Know

Dare Bioscience (DARE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 5 months ago

DARE
-0.34%

Performance Overview

Return	DARE	S&P 500 (^GSPC)
YTD	-7.37%	-4.26%
1-Year	-22.31%	+8.55%
3-Year	-77.91%	+36.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Daré Bioscience, Inc. (DARE)

Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025

Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women’s Health Innovation

Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year

Q4 2024 Dare Bioscience Inc Earnings Call

Dare Bioscience Inc (DARE) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial ...

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)

Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Q3 2024 Dare Bioscience Inc Earnings Call

Dare Bioscience Inc (DARE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites

Dare Bioscience (DARE) Upgraded to Buy: Here's What You Should Know

Performance Overview